Drug intelligence / Profile preview

astatine-211-labeled gold nanoparticle–single-domain antibody conjugate

Development stage
Preclinical
Lead developer
Osaka University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Astatine-211-labeled gold nanoparticle–single-domain antibody conjugate ([211At]At-AuNP-ABDMPL16) is a preclinical-stage targeted alpha therapy (TAT) radiopharmaceutical. It consists of a single-domain antibody (ABDMPL16) targeting programmed cell death 1 ligand 1 (PD-L1) stably conjugated to the surface of a gold nanoparticle (AuNP) core and radiolabeled with the alpha-emitting radionuclide astatine-211 (211At). The gold nanoparticle platform provides high radiochemical stability and prevents deastatination in vivo, while the single-domain antibody ensures rapid tumor penetration and highly specific targeting of PD-L1-expressing cancer cells. Upon internalization, the high-energy, short-range alpha particles emitted by astatine-211 induce lethal double-strand DNA breaks in tumor cells, minimizing damage to surrounding healthy tissues. It is being investigated for the treatment of solid tumors, particularly melanoma.

Other names
astatine-211-labeled gold nanoparticle-single-domain antibody conjugateastatine211-labeled gold nanoparticle-single-domain antibody conjugateastatine 211-labeled gold nanoparticle-single-domain antibody conjugateastatine-211-labeled gold nanoparticle–single-domain antibody conjugate
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Nanobodies (VHH)Antibody-Radionuclide ConjugatesAlpha EmittersNanoparticles
03

Pharmacology

04

Development

IndicationHighest phaseStatus
melanomaPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Osaka UniversityLead developer
07

Competitive landscape

Drugs on the same target
214
Drugs in the lead indication
803

Lead indication: melanoma

Most advanced in the lead indication

  1. ADC 3Approved
  2. aldesleukinApproved
  3. avelumabApproved
  4. cosibelimab-ipdlApproved
  5. dacarbazineApproved

Beyond the preview

Go deeper on astatine-211-labeled gold nanoparticle–single-domain antibody conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on astatine-211-labeled gold nanoparticle–single-domain antibody conjugate.

Work on astatine-211-labeled gold nanoparticle–single-domain antibody conjugate? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call